Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.32 |
| ▸ | DRD3 | P35462 | 2/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.31 |
| ▸ | TACR2 | P21452 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28843653 | 0.84 | MAPT (0.36) | KDM4EALDH1A1POLBTDP1MAPT | |
| SCHEMBL10175171 | 0.82 | DAO (0.38) | KDM4EALDH1A1POLBSIGMAR1DAO | |
| SCHEMBL685503 | 0.79 | PAOX (0.36) | KDM4EALDH1A1POLBTDP1 | |
| SCHEMBL6049095 | 0.76 | MAPT (0.48) | ALDH1A1POLBL3MBTL1MAPTPKM | |
| SCHEMBL8007175 | 0.75 | TPI1 (0.32) | MAPT | |
| SCHEMBL14268088 | 0.72 | POLB (0.39) | ALDH1A1POLBSIGMAR1HRH3 | |
| SCHEMBL10240791 | 0.71 | HRH3 (0.38) | KCNH2HRH3 | |
| SCHEMBL19361712 | 0.71 | DAO (0.35) | KDM4EALDH1A1SIGMAR1DAOMAOB | |
| SCHEMBL13257752 | 0.71 | HRH3 (0.33) | KDM4EALDH1A1KCNH2HRH3CYP2D6 | |
| SCHEMBL18705243 | 0.71 | ANPEP (0.39) | POLBSIGMAR1KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2018-05-03 | — | — | US | disclosed |
| US-9828378-B2 | Kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9724354-B2 | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | INTELLIKINE LLC | 2017-07-27 | — | — | US | disclosed |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | FAETH THERAPEUTICS, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CALITHERA BIOSCIENCES, INC. | 2016-10-06 | — | — | US | disclosed |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | INTELLIKINE LLC | 2016-10-06 | — | — | US | disclosed |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARMACEUTICALS, INC. | 2016-09-22 | — | — | US | disclosed |
| US-9345706-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE, LLC (US) | 2016-05-24 | — | — | US | disclosed |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | INTELLIKINE LLC | 2016-03-31 | — | — | US | disclosed |
| US-8476431-B2 | Benzoxazole kinase inhibitors and methods of use | Itellikine LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8476282-B2 | Benzoxazole kinase inhibitors and methods of use | INTELLIKINE LLC (US) | 2013-07-02 | — | — | US | disclosed |
| US-8450329-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-8450480-B2 | — | — | 2013-05-28 | — | — | US | disclosed |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | INTELLIKINE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-07-14 | — | — | US | disclosed |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-05-26 | — | — | US | disclosed |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | INTELLIKINE LLC | 2011-03-31 | — | — | US | disclosed |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-29 | — | — | US | disclosed |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | FAETH THERAPEUTICS, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172228-A1 | KINASE INHIBITORS AND METHODS OF USE | PIK3CA, MTOR, PDPK1 | KDM4E 1108/4885ALDH1A1 4685/4885POLB 2650/4885 |
| US-20160287596-A1 | Benzoxazole Kinase Inhibitors and Methods of Use | BMX, MTOR, PDPK1 | KDM4E 992/4885ALDH1A1 4042/4885POLB 3912/4885 |
| US-20100184760-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | KDM4E 992/4885ALDH1A1 4042/4885POLB 3912/4885 |
| US-20160287595-A1 | Combination Pharmaceutical Compositions and Uses Thereof | CDC25C, CCNC, CDC25B | KDM4E 1873/4885ALDH1A1 2340/4885POLB 313/4885 |
| US-20110077268-A1 | KINASE INHIBITORS AND METHODS OF USE | MAP3K20, MAP3K1, PDPK1 | KDM4E 770/4885ALDH1A1 4739/4885POLB 1654/4885 |
| US-20110124641-A1 | BENZOTHIAZOLE KINASE INHIBITORS AND METHODS OF USE | MTOR, PDPK1, PIKFYVE | KDM4E 529/4885ALDH1A1 4673/4885POLB 3346/4885 |
| US-20160089371-A1 | Combination of Kinase Inhibitors and Uses Thereof | MTOR, PIK3CA, AKT1 | KDM4E 2247/4885ALDH1A1 4335/4885POLB 3205/4885 |
| US-20180117060-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, MTOR, AURKA | KDM4E 1551/4885ALDH1A1 4335/4885POLB 1687/4885 |
| US-20160271140-A1 | COMBINATION OF CATALYTIC MTORC 1/2 INHIBITORS AND SELECTIVE INHIBITORS OF AURORA A KINASE | AURKC, AURKA, AURKB | KDM4E 1898/4885ALDH1A1 3927/4885POLB 1620/4885 |
| US-20100190749-A1 | Benzoxazole kinase inhibitors and methods of use | BMX, MTOR, PDPK1 | KDM4E 992/4885ALDH1A1 4042/4885POLB 3912/4885 |
| US-20170209448-A1 | TREATMENT REGIMENS USING MULTIPLE PHARMACEUTICAL AGENTS | MPL, MTX2, SLC10A1 | KDM4E 3933/4885ALDH1A1 1326/4885POLB 1201/4885 |
| US-20160287597-A1 | Treatment Regimens Using Multiple Pharmaceutical Agents | MPL, MTX2, SLC10A1 | KDM4E 3933/4885ALDH1A1 1326/4885POLB 1201/4885 |
| US-20110281866-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K13, MAP3K3, CDK3 | KDM4E 1473/4885ALDH1A1 3979/4885POLB 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.